Therefore, the availability of additional markers other than AMH and AFC to predict outcomes and allow the development of more specific and tailored protocols will be of great benefit to women with breast cancer, most of whom have only one opportunity to undergo FP before chemotherapy. This evidence concerns the gene AMH and breast carcinoma.